Data Access Proposal Request
Flatiron Health UK RWD Products
-
Prostate cancer
Attendees
Flatiron Health UK
-
Adam Manhi (chair)
-
Emma Salib (programme manager)
Research Transparency Panel
-
Jennifer McCaffery (lay)
-
Hayley Hall (lay)
-
Sonia Patton (patient)
-
Trishna Bharadia (patient)
-
Yanrong Jiang (clinical)
Conflicts of interest
No conflicts declared by panel
Decision outcome
Approved
Summary of discussion
-
Broad agreement the lay summary was clear, well-written and easy to follow.
-
Clear cohort with unmet need and limited treatment options which become less effective over time.
-
Comprehensive explanation of use cases, including analyses and patient benefit.
-
Clear case for why access to RWD is required, giving more representative insights than clinical trials.
-
Transparent explanation of previous work with Flatiron and positive impact.
-
The panel raised several comments on other aspects of the application including:
-
Patient cohort with ‘unmet need’ could have been elaborated on further (e.g. # patients; survival rates; side effects of current medications).
-
Further detail on Novartis plans for indications in metastatic prostate cancer would be appreciated.
-
More detail could have been provided on DEI (e.g. existing health inequalities; examples of Novartis’ DEI work).
-
Would have liked more information on how Novartis would engage with patients through the process, including integrating feedback and disseminating findings.
-